Day: November 12, 2019

PITTSBURGH, Nov. 12, 2019 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, announced today that Dietrich Stephan, Chief Executive Officer of NeuBase, will present a corporate overview and business update at the Stifel 2019 Healthcare Conference, which is being held from November 19th to 20th in New York City.About NeuBase TherapeuticsNeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds...

Ramat Gan, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) —  Internet Gold – Golden Lines Ltd. (the “Company” or “Internet Gold”) (NASDAQ Global Select Market and TASE: IGLD).Further to the Company’s previous announcements with respect of the ‘Searchlight Transaction‘, the Company today announced that the anticipated schedule for closing of the Searchlight Transaction is December 2, 2019.There is no guarantee that the Searchlight Transaction will be completed, and if completed, the timing of closing of the transaction.As previously announced, if the Searchlight Transaction is completed, the Company will not be able to fully pay its debts, and the Company intends to initiate a creditors’ arrangement which would be submitted to the applicable Israeli court. The Company anticipates that pursuant to such arrangement the existing shares...

VANCOUVER, British Columbia, Nov. 12, 2019 (GLOBE NEWSWIRE) — Maxtech Ventures Inc. (“Maxtech” or the “Company”) (CSE: MVT) (Frankfurt: M1N) (OTC: MTEHF), the Company is pleased to announce the appointment of Red Lake gold mining district trailblazer James Rogers to Senior Vice President, Exploration. Jim will be responsible for all exploration activities of the Company, starting immediately at the Panama Lake project. He will join the current team in the preparation and execution of its exploration strategy at all levels, plans and budgets including managing contractors and suppliers, where required.Appointment of James RogersJames Rogers is a geologist with forty years of experience in the gold mining and exploration industry. Starting as a mine geologist in 1980, Jim spent almost thirty years in the Red Lake Gold mining camp...

BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) — The New Ireland Fund, Inc. (NYSE: IRL) today released an updated Monthly portfolio statement as of October 31, 2019.The holdings are subject to change at any point in time hereafter.Investment Objective: The New Ireland Fund, Inc. (NYSE: IRL), a closed-end non-diversified investment company, seeks long-term capital appreciation through investment of at least 80% of its assets in a portfolio of Irish securities.The New Ireland Fund, Inc. is managed by KBI Global Investors (North America) Ltd, a wholly owned subsidiary of KBI Global Investors Ltd, and is listed on the New York Stock Exchange under the ticker symbol IRL.  For further information, please contact the Fund at (800) 468-6475 or investor.query@newirelandfund.com Website:   newirelandfund.com 

Oslo, Norway, November 12, 2019 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present at BIO-Europe 2019 being held November 11-13, 2019 at Hamburg Messe, Germany.On Wednesday, November 13, 2019 at 09:15am (CET), Dr. Per Walday, CEO, will present an overview of PCI Biotech’s technology and the multiple business development and commercial opportunities available based on this proprietary platform. The presentation will be made available on PCI Biotech’s website (www.pcibiotech.com ) under “Other presentations”.About PCI Biotech         PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI)...

NOVA LIMA, Brazil, Nov. 12, 2019 (GLOBE NEWSWIRE) — Afya Limited, or Afya (Nasdaq: AFYA) today published its normalized sell-side’s consensus estimates for 3Q19, with the contributions of analysts who cover Afya on a regular basis.Afya collected the estimates between November 1 and November 11, 2019, directly from the analysts, who normalized their estimates for comparability in terms of the impact of IFRS 16.Afya will report second quarter 2019 financial results for the period ended September 30, 2019, following the close of the market on Friday, November 29, 2019.The Company will host a corresponding conference call and webcast on December 2 at 1:00 p.m. Eastern time on that day.DisclaimerThe consensus estimate is based on estimates, forecasts and predictions made by third party financial analysts. It is not prepared based on...

The company has received notifications about transactions in the issuer’s securities.The person authorized to provide additional information:Kazimieras TonkūnasINVL Technology Managing Partnere-mail k.tonkunas@invltechnology.ltAttachmentsINVL Technology_notification_Invalda INVL_08 11 2019INVL Technology_notification_Invalda INVL_11 11 2019

Pateikiame gautus pranešimus apie sandorius SUTPKIB „INVL Technology“ akcijomis.Asmuo, įgaliotas suteikti papildomą informaciją:Kazimieras TonkūnasUTIB „INVL Technology“ vadovaujantis partnerisEl. paštas k.tonkunas@invltechnology.ltPriedaiINVL Technology_vadovu sandoris_Invalda INVL_2019 11 08INVL Technology_vadovu sandoris_Invalda INVL_2019 11 11